BCL2 and cancer: Administration of Res sensitizes cancer cells to apoptosis via NF-κB down-regulation leading to a decrease in the level of anti-apoptotic factor Bcl-2 and an increase in apoptotic factors caspase-3 and caspase-8 [121].